Business Wire

Egypt Captivates World with Golden Pharaoh Parade

Share

Twenty-two pharaoh mummies walked the streets of Cairo on Saturday evening in a stunning royal procession from the Egyptian Museum on Tahrir Square to the new National Museum of Egyptian Civilization (NMEC) in Fustat. The event marked the official launch of NMEC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210403005008/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Egypt Captivates World with Golden Pharaoh Parade (Photo: AETOSWire)

Against the backdrop of fireworks, the mummies – 18 kings and four queens – travelled in order of age on purpose-built gold-colored pharaonic chariots, equipped with an air ride suspension system to absorb vibrations, and bearing the name of their occupants in Arabic, English, and hieroglyphics. Seqenenre Tao II, who reigned over Upper Egypt around 1,600 BCE, led the parade, while Ramses IX, who ruled in the 12th century BCE, brought up the rear. In line with strict international standards for the transport of artifacts, the royal remains were placed in state-of-the-art sterile display cases to guarantee their immaculate preservation.

Accompanying the mummies were 60 motorcycles, 150 horses, and a pharaonic music ensemble conducted by renowned Egyptian maestro Nader Abbassi. The procession commenced with a 21-gun salute, circled the obelisk at the nearby Tahrir Square, and then proceeded along the Nile to NMEC, where Egyptian President Abdel Fattah El-Sisi personally welcomed the mummies to their new permanent home in Fustat, the National Museum of Egyptian Civilization. The 40-minute parade drew participation of 12 Egyptian celebrities, being broadcast by 200+ global TV channels.

The priceless artifacts will spend the next two weeks in NMEC’s laboratory, where they will be prepared for installation inside the Royal Mummies Hall, modeled on the Valley of the Kings. The Royal Mummies Hall will open to visitors on April 18, coinciding with World Heritage Day.

To promote its launch, NMEC offers a 50 percent discount on entry ticket prices to the Central Exhibition Hall for all visitors from April 4 to 17. In addition, representatives of local and international media have the opportunity to photograph and film the artifacts inside the Central Exhibition Hall for free on April 4 and 5.

Overlooking Ain Al Sira in the heart of the historical city of Fustat near the Babylon Fortress, NMEC is one of the largest and most important archeology museums in the world, and the first to span the entirety of the Egyptian civilization.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

APCO Worldwide
Shady ElGohary
Account Director, +971552424797
selgohary@apcoworldwide.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye